Welcome to our dedicated page for Tivic Health Systems SEC filings (Ticker: TIVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tivic Health Systems, Inc. (TIVC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Tivic files a range of reports with the U.S. Securities and Exchange Commission that outline its immunotherapeutics strategy, licensing agreements, financings and governance matters.
Investors can review Tivic’s current reports on Form 8‑K, which describe material events such as the exclusive license and amended and restated license agreement for the TLR5 agonist programs Entolimod and Entolasta, the transfer of investigational new drug applications (INDs) for Entolimod, and the acquisition of contract development and manufacturing organization (CDMO) assets used to form Velocity Bioworks. Other 8‑K filings detail executive employment agreements, equity incentive plan amendments, transfer agent changes and shareholder meeting results.
Registration statements like the S‑1/A shed light on Tivic’s status as an emerging growth and smaller reporting company, the registration of common stock and warrants held by selling stockholders, and the structure of preferred stock and convertible securities. These documents help explain how Tivic raises capital to support its biologics and bioelectronic programs.
On this page, Stock Titan surfaces Tivic’s 10‑K annual reports and 10‑Q quarterly reports when available, which typically include risk factors, management’s discussion and analysis, and detailed descriptions of the company’s dual‑platform strategy in biologics and bioelectronic medicine. Form 4 and related ownership filings, when present, can be used to monitor insider equity transactions and incentive awards tied to Tivic’s equity plans.
Stock Titan enhances Tivic’s filings with AI-generated summaries that highlight key terms in license agreements, financing structures, and manufacturing commitments, helping readers quickly identify items such as Entolimod development milestones, Velocity Bioworks obligations, and voting outcomes from shareholder meetings. Real-time EDGAR updates ensure that new Tivic filings appear promptly, while structured views make it easier to navigate between 8‑K events, registration statements and periodic reports for a more complete understanding of TIVC’s regulatory and corporate history.
Tivic Health Systems, Inc. (TIVC) filed an 8-K to disclose that it has entered into an Amended & Restated Exclusive License Agreement (A&R License) with Statera Biopharma covering the TLR5 agonist programs Entolimod and Entolasta. The new agreement fully supersedes the original license executed on 11 Feb 2025.
Key changes versus the February 2025 agreement:
- Royalty flexibility – future royalties may be paid in cash or in Tivic common stock, solely at Tivic’s discretion. This could conserve cash but may cause shareholder dilution if equity is used.
- Directed payments – aside from the original license fee already paid, up to an additional $5.6 million in milestone or other payments owed to Statera will be remitted directly to Avenue Capital on Statera’s behalf.
All other material terms, including Tivic’s worldwide exclusivity for the Acute Radiation Syndrome indication and its option on additional indications (Lymphocyte Exhaustion, Immunosenescence, Neutropenia, Vaccine Adjuvant), remain unchanged.
Strategic implications: The amended structure preserves Tivic’s strategic control of a potentially high-value immunomodulatory asset while improving liquidity management through optional equity settlement. However, the commitment to fund up to $5.6 million—whether in cash or shares—represents a meaningful obligation for a micro-cap issuer and may introduce dilution or leverage pressure depending on financing choices.
Tivic Health Systems (NASDAQ:TIVC), an emerging growth company, filed an 8-K announcing the completion of their Optimization Study for a non-invasive vagus nerve stimulation device. The announcement was made via press release on June 25, 2025. The filing is being furnished under Regulation FD disclosure rules and includes standard forward-looking statements disclaimers. The company's interim CFO, Lisa Wolf, signed the filing.